Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

NewLink Genetics

Nasdaq:NLNK
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NLNK
Nasdaq
$33M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • NewLink Genetics has significant price volatility in the past 3 months.
NLNK Share Price and Events
7 Day Returns
-23.9%
NasdaqGM:NLNK
-6.3%
US Biotechs
-9.3%
US Market
1 Year Returns
-57%
NasdaqGM:NLNK
-3.9%
US Biotechs
-12.6%
US Market
NLNK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NewLink Genetics (NLNK) -23.9% -43.7% -52.2% -57% -95.6% -98.2%
US Biotechs -6.3% -13.9% -11.3% -3.9% 6.1% -12.9%
US Market -9.3% -26.2% -22.1% -12.6% 5.2% 17.8%
1 Year Return vs Industry and Market
  • NLNK underperformed the Biotechs industry which returned -3.9% over the past year.
  • NLNK underperformed the Market in United States of America which returned -12.6% over the past year.
Price Volatility
NLNK
Industry
5yr Volatility vs Market
Related Companies

Value

 Is NewLink Genetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NewLink Genetics. This is due to cash flow or dividend data being unavailable. The share price is $0.89.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NewLink Genetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NewLink Genetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:NLNK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.15
NasdaqGM:NLNK Share Price ** NasdaqGM (2020-03-18) in USD $0.89
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 16.03x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 12.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NewLink Genetics.

NasdaqGM:NLNK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NLNK Share Price ÷ EPS (both in USD)

= 0.89 ÷ -1.15

-0.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NewLink Genetics is loss making, we can't compare its value to the US Biotechs industry average.
  • NewLink Genetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does NewLink Genetics's expected growth come at a high price?
Raw Data
NasdaqGM:NLNK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
21.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 1.03x
United States of America Market PEG Ratio Median Figure of 2,003 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NewLink Genetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NewLink Genetics's assets?
Raw Data
NasdaqGM:NLNK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.11
NasdaqGM:NLNK Share Price * NasdaqGM (2020-03-18) in USD $0.89
United States of America Biotechs Industry PB Ratio Median Figure of 427 Publicly-Listed Biotechs Companies 2.18x
United States of America Market PB Ratio Median Figure of 5,135 Publicly-Listed Companies 1.22x
NasdaqGM:NLNK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NLNK Share Price ÷ Book Value per Share (both in USD)

= 0.89 ÷ 2.11

0.42x

* Primary Listing of NewLink Genetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NewLink Genetics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess NewLink Genetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NewLink Genetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NewLink Genetics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NewLink Genetics expected to grow at an attractive rate?
  • NewLink Genetics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • NewLink Genetics's earnings growth is expected to exceed the United States of America market average.
  • NewLink Genetics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:NLNK Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:NLNK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 21.5%
NasdaqGM:NLNK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 56%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.8%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:NLNK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:NLNK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 212 65 1
2023-12-31 57 -58 1
2022-12-31 6 -70 1
2021-12-31 8 -59 1
2020-12-31 48 -8 1
2020-03-19
NasdaqGM:NLNK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -30 -43
2019-09-30 1 -23 -45
2019-06-30 1 -32 -38
2019-03-31 3 -31 -45
2018-12-31 12 -38 -54
2018-09-30 22 -54 -57
2018-06-30 28 -46 -70
2018-03-31 36 -50 -69
2017-12-31 29 -48 -72
2017-09-30 31 -48 -72
2017-06-30 41 -54 -67
2017-03-31 33 -59 -82

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NewLink Genetics's earnings are expected to grow significantly at over 20% yearly.
  • NewLink Genetics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:NLNK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from NewLink Genetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NLNK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 9.63 9.63 9.63 1.00
2023-12-31 -9.90 -9.90 -9.90 1.00
2022-12-31 -12.15 -12.15 -12.15 1.00
2021-12-31 -13.59 -13.59 -13.59 1.00
2020-12-31 -1.98 -1.98 -1.98 1.00
2020-03-19
NasdaqGM:NLNK Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.15
2019-09-30 -1.22
2019-06-30 -1.02
2019-03-31 -1.22
2018-12-31 -1.44
2018-09-30 -1.53
2018-06-30 -1.98
2018-03-31 -2.08
2017-12-31 -2.30
2017-09-30 -2.44
2017-06-30 -2.29
2017-03-31 -2.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NewLink Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NewLink Genetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NewLink Genetics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NewLink Genetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NewLink Genetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NewLink Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NewLink Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NewLink Genetics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NewLink Genetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NewLink Genetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NLNK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.94 -42.99 20.57
2019-09-30 0.71 -45.29 21.21
2019-06-30 0.58 -38.14 23.42
2019-03-31 2.68 -45.32 25.69
2018-12-31 12.47 -53.60 28.42
2018-09-30 22.37 -56.71 30.48
2018-06-30 27.73 -69.94 29.70
2018-03-31 35.85 -69.35 30.68
2017-12-31 28.71 -71.95 30.63
2017-09-30 31.32 -71.77 31.12
2017-06-30 41.18 -66.69 31.56
2017-03-31 32.82 -82.35 31.80
2016-12-31 35.77 -85.16 33.23
2016-09-30 30.72 -93.22 33.23
2016-06-30 29.58 -93.59 33.36
2016-03-31 35.01 -75.29 31.49
2015-12-31 68.50 -40.38 30.69
2015-09-30 230.09 101.21 31.29
2015-06-30 218.69 111.52 28.84
2015-03-31 211.45 116.44 24.44
2014-12-31 172.59 96.02 19.33
2014-09-30 3.64 -32.04 14.04
2014-06-30 1.11 -34.57 11.37
2014-03-31 1.13 -32.48 10.77
2013-12-31 1.09 -31.18 9.52
2013-09-30 1.10 -29.45 8.63
2013-06-30 1.16 -27.18 7.76
2013-03-31 1.52 -26.41 7.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NewLink Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NewLink Genetics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NewLink Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NewLink Genetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NewLink Genetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NewLink Genetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NewLink Genetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NewLink Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NewLink Genetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NewLink Genetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2195.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NewLink Genetics Company Filings, last reported 2 months ago.

NasdaqGM:NLNK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 78.88 0.04 90.55
2019-09-30 86.40 0.06 98.53
2019-06-30 98.69 0.07 105.37
2019-03-31 107.02 0.09 113.18
2018-12-31 115.14 0.10 120.74
2018-09-30 122.20 0.13 122.06
2018-06-30 124.95 0.17 137.07
2018-03-31 137.95 0.20 143.89
2017-12-31 151.56 0.27 158.71
2017-09-30 106.46 0.33 120.70
2017-06-30 102.60 0.40 107.78
2017-03-31 114.35 0.46 118.24
2016-12-31 129.47 0.52 131.49
2016-09-30 138.28 0.58 148.28
2016-06-30 149.34 0.64 160.53
2016-03-31 176.81 0.62 177.98
2015-12-31 195.77 0.94 197.80
2015-09-30 207.41 0.97 200.36
2015-06-30 225.76 1.01 207.58
2015-03-31 232.83 1.05 214.37
2014-12-31 196.94 1.10 202.80
2014-09-30 70.39 1.18 67.71
2014-06-30 72.60 1.13 77.11
2014-03-31 79.83 1.18 83.96
2013-12-31 58.33 1.19 61.54
2013-09-30 47.35 1.08 51.96
2013-06-30 54.36 1.13 59.29
2013-03-31 59.99 1.14 64.03
  • NewLink Genetics's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0.6% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NewLink Genetics has sufficient cash runway for more than 3 years based on current free cash flow.
  • NewLink Genetics has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 24.2% each year.
X
Financial health checks
We assess NewLink Genetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NewLink Genetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NewLink Genetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NewLink Genetics dividends.
If you bought $2,000 of NewLink Genetics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NewLink Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NewLink Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:NLNK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 64 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1971 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:NLNK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-19

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NewLink Genetics has not reported any payouts.
  • Unable to verify if NewLink Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NewLink Genetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NewLink Genetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NewLink Genetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NewLink Genetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NewLink Genetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NewLink Genetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • NewLink Genetics has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the NewLink Genetics management team in years:

1.7
Average Tenure
50
Average Age
  • The average tenure for the NewLink Genetics management team is less than 2 years, this suggests a new team.
Management Team

Gene Kennedy

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
50
TENURE
2.3 yrs

Carl Langren

TITLE
CFO & Secretary
COMPENSATION
$843K
AGE
64
TENURE
1.7 yrs

Lisa Miller

TITLE
Director of Investor Relations

Brad Powers

TITLE
General Counsel
AGE
40
TENURE
1.7 yrs

Mario Mautino

TITLE
Senior VP of Drug Discovery & Intellectual Property Officer
AGE
53

Lori Lawley

TITLE
Senior VP of Finance & Controller
AGE
35
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the NewLink Genetics board of directors in years:

4.7
Average Tenure
59
Average Age
  • The tenure for the NewLink Genetics board of directors is about average.
Board of Directors

Tom Raffin

TITLE
Lead Independent Director
COMPENSATION
$204K
AGE
72

Lota Zoth

TITLE
Independent Director
COMPENSATION
$181K
AGE
59
TENURE
7.3 yrs

Chad Johnson

TITLE
Independent Director
COMPENSATION
$393K
AGE
40
TENURE
2 yrs

Ernest Talarico

TITLE
Independent Director
COMPENSATION
$175K
AGE
48
TENURE
21.2 yrs

Matt Sherman

TITLE
Independent Director
COMPENSATION
$359K
AGE
63
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess NewLink Genetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NewLink Genetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Worry About NewLink Genetics Corporation's (NASDAQ:NLNK) CEO Pay?

Check out our latest analysis for NewLink Genetics How Does Charles Link's Compensation Compare With Similar Sized Companies? … Thus we can conclude that Charles Link receives more in total compensation than the median of a group of companies in the same market, and of similar size to NewLink Genetics Corporation. … We compared the total CEO remuneration paid by NewLink Genetics Corporation, and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

What Kind Of Shareholder Owns Most NewLink Genetics Corporation (NASDAQ:NLNK) Stock?

Insider Ownership Of NewLink Genetics The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Private Company Ownership Our data indicates that Private Companies hold 21%, of the company's shares. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Simply Wall St -

Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. … What this means for you: Beta only tells us that the NewLink Genetics share price is sensitive to broader market movements.

Simply Wall St -

Those Who Purchased NewLink Genetics (NASDAQ:NLNK) Shares Five Years Ago Have A 93% Loss To Show For It

While it may not be enough for some shareholders, we think it is good to see the NewLink Genetics Corporation (NASDAQ:NLNK) share price up 12% in a single quarter. … Given that NewLink Genetics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Over half a decade NewLink Genetics reduced its trailing twelve month revenue by 21% for each year.

Simply Wall St -

Can We See Significant Institutional Ownership On The NewLink Genetics Corporation (NASDAQ:NLNK) Share Register?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … NewLink Genetics is not a large company by global standards. … institutions own shares in the company.

Simply Wall St -

NewLink Genetics Corporation (NASDAQ:NLNK): Is It A Good Long Term Opportunity?

The latest earnings release NewLink Genetics Corporation's (NASDAQ:NLNK) announced in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Should You Worry About NewLink Genetics Corporation's (NASDAQ:NLNK) CEO Pay?

Charles Link has been the CEO of NewLink Genetics Corporation (NASDAQ:NLNK) since 2003. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Charles Link's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For NewLink Genetics Corporation (NASDAQ:NLNK)?

If you're interested in NewLink Genetics Corporation (NASDAQ:NLNK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Could The NewLink Genetics Corporation (NASDAQ:NLNK) Ownership Structure Tell Us Something Useful?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We also tend to see lower insider ownership in companies that were previously publicly owned. … NewLink Genetics is a smaller company with a market capitalization of US$72m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

How Does Investing In NewLink Genetics Corporation (NASDAQ:NLNK) Impact Your Portfolio?

If you're interested in NewLink Genetics Corporation (NASDAQ:NLNK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

Company Info

Description

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Details
Name: NewLink Genetics Corporation
NLNK
Exchange: NasdaqGM
Founded: 1999
$33,222,298
37,328,425
Website: http://www.newlinkgenetics.com
Address: NewLink Genetics Corporation
2503 South Loop Drive,
Suite 5100,
Ames,
Iowa, 50010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NLNK Common Stock Nasdaq Global Market US USD 14. Nov 2011
DB 4NX Common Stock Deutsche Boerse AG DE EUR 14. Nov 2011
Number of employees
Current staff
Staff numbers
21
NewLink Genetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/19 02:39
End of day share price update: 2020/03/18 00:00
Last estimates confirmation: 2020/02/28
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.